Logo

Course

Antiretroviral Therapy Updates with Protocol for Rapid Initiation

Details

Published Date: 07/20/2022

Expiration Date: 10/20/2024

CE Credit: No CE

Description

This course will ensure that clinicians will have the working knowledge of evidence that supports rapid start of antiretroviral treatment for people with HIV infection, data supporting HIV treatment as prevention and the “Undetectable = Untransmittable” statement as a Public Health campaign, safe and efficacious rapid ART regimens based on known patient characteristics, as well as regimens to avoid, and patient-level and institutional barriers and best practices for implementation.

Please note: 

Since we created this presentation, New York State updated its Rapid ART guidelines. “Clinicians should offer rapid initiation of ART—preferably on the same day or within 72 hours—to all individuals who are candidates for rapid ART initiation and who have a confirmed HIV diagnosis or a reactive HIV screening result pending results of a confirmatory HIV test or suspected acute HIV infection, i.e., HIV antibody negative and HIV RNA positive.” This presentation includes the outdated recommendation of 96 hours. 

Presenter(s)

Asa Radix,MD, MPH, FACP
Asa Radix, MD, MPH, FACP is the Senior Director of Research and Education and a Clinical Associate Professor of Medicine at New York University. Dr. Radix has over 20 years of experience providing primary care and hormone therapy to transgender and gender non-binary people. Dr. Radix has assisted in developing national and international guidelines in transgender health. Dr. Radix is currently co-chair of the World Professional Association of Transgender Health (WPATH) Standards of Care 8 revision committee, and serves on the AIDS Institute’s Medical Clinical Care Committee and the DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents

Learning Objectives

  • Discuss evidence that supports rapid start of antiretroviral treatment for people with HIV infection.
  • Review data supporting HIV treatment as prevention and the “Undetectable = Untransmittable” statement as a Public Health campaign.
  • Identify safe and efficacious rapid ART regimens based on known patient characteristics, as well as regimens to avoid.
  • Describe patient-level and institutional barriers and best practices for implementation.

Continuing Education Credit Information